Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions

被引:48
作者
Kim, MS
Na, HJ
Han, SW
Jin, JS
Song, UY
Lee, EJ
Song, BK
Hong, SH
Kim, HM
机构
[1] Kyung Hee Univ, Coll Oriental Med, Dept Pharmacol, Seoul 130701, South Korea
[2] Wonkwang Univ, Coll Pharm, Dept Oriental Pharm, Iksan 571749, Jeonbuk, South Korea
[3] Wonkwang Univ, Coll Oriental Med, Iksan 570749, Jeonbuk, South Korea
关键词
Forsythia fructus; mast cells; oedema; histamine; tumor necrosis factor-alpha;
D O I
10.1023/A:1023865727780
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mast cells are key as effector cells in the early phase allergic inflammation and in diverse immunological and pathological processes. Forsythia fructus (F. fructus) has used as a traditional medicine for inflammatory diseases. In the present study, we determined the effect of F. fructus extracts on compound 48/80-induced paw oedema and vascular permeability in vivo. In addition, we investigated in vitro whether F. fructus has inhibitory effects on compound 48/80-induced histamine releases from rat peritoneal mast cells (RPMC), and on phorbol 12-myristate 13-acetate (PMA) plus A23187-induced tumor necrosis factor-alpha (TNF-alpha) releases from human mast cells (HMC-1). In mice orally administrered F. fructus (100 mug/g) for 1 h, compound-48/80-induced oedema and vascular permeability were significantly reduced rather than those receiving intravenous injection of ketotifen, mast cell stabilizer. F. fructus dose-dependently inhibited the histamine release induced by compound 48/80 from RPMCs. Moreover, F. fructus had no cytotoxic effects on cell viability and had inhibitory effects on TNF-alpha secretion from HMC-1. These results suggest that F. fructus is a potential herb medicine for treatment of inflammatory diseases through downmodulating mast cell activation.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 43 条
[31]  
Ozaki Y, 2000, BIOL PHARM BULL, V23, P365, DOI 10.1248/bpb.23.365
[32]   MAST-CELLS - FUNCTION, DIFFERENTIATION AND ACTIVATION [J].
PEARCE, FL .
CURRENT OPINION IN IMMUNOLOGY, 1989, 1 (04) :630-636
[33]  
Queralt M, 1998, DRUG DEVELOP RES, V44, P49, DOI 10.1002/(SICI)1098-2299(199806/07)44:2/3&lt
[34]  
49::AID-DDR1&gt
[35]  
3.0.CO
[36]  
2-A
[37]   In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1 [J].
Queralt, M ;
Brazís, P ;
Merlos, M ;
de Mora, F ;
Puigdemont, A .
INFLAMMATION RESEARCH, 2000, 49 (07) :355-360
[38]   Cytokines and chemoattractants in allergic inflammation [J].
Romagnani, S .
MOLECULAR IMMUNOLOGY, 2002, 38 (12-13) :881-885
[39]   The role of lymphocytes in allergic disease [J].
Romagnani, S .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (03) :399-408
[40]   Involvement of mast cells, sensory afferents and sympathetic mechanisms in paw oedema induced by adenosine A1 and A2B/3 receptor agonists [J].
Sawynok, J ;
Reid, A ;
Liu, XJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 395 (01) :47-50